Biotech By Adam Feuerstein and Damian Garde Q&A: How biotech analysts navigate fickle markets, pushy investors, and ‘vindictive’ CEOs
Politics By Erin Mershon House poised to pass bill critical for drug industry; the Senate may be a slog
First Opinion By Dana P. Goldman and Darius Lakdawalla Election verdict: Pharma needs a new prescription
First Opinion By Henry A. Waxman and Bill Corr Waste from pharmaceutical plants in India and China promotes antibiotic-resistant superbugs
Business By Damian Garde The EpiPen was her ‘baby.’ Now this pharma CEO is in the hot seat over price hikes
In the Lab By Helen Branswell The race for a Zika vaccine is intense. But it may be missing the most important players
The Pharmalot View By Ed Silverman The ‘gouge factor’: Big companies want transparency in drug price negotiations
First Opinion By Charles D. Rosen Say what you will about Donald Trump. He’s right about drug companies
Business By Charles Ornstein and Ryann Grochowski Jones — ProPublica Drug and device makers find receptive audience at for-profit, Southern hospitals
Biotech By Meghana Keshavan and Rebecca Robbins Post-Brexit, will the European Medicines Agency be homeless?